Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Editorial

Marijuana is not a prescription medicine

John Fletcher
CMAJ March 19, 2013 185 (5) 369; DOI: https://doi.org/10.1503/cmaj.130267
John Fletcher
John Fletcher is Editor-in-Chief, .
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

What role should doctors play in the control of marijuana? Health Canada in a news release late last year announced proposals for “new Marihuana for Medical Purposes Regulations,” suggesting that “changes improve public safety [and] maintain patient access.”1 The document goes on to suggest that “the proposed new Marihuana for Medical Purposes Regulations aim to treat marihuana as much as possible like any other narcotic used for medical purposes.”1 Under the existing regulations, it is the federal minister of health who issues a patient with authorization to possess marijuana. Under the proposed new regulations, it is doctors, or possibly other health practitioners, who will issue “a medical document, similar to a prescription” allowing their patient to obtain marijuana. The language is soothing and suggests that marijuana is a medicine, albeit one that needs special oversight like morphine and for which users may be seen as patients in certain circumstances. It is but a small step from here to suggest that doctors should prescribe marijuana for medical indications. But is marijuana a medicine? Or, more specifically, is it a prescription medicine?

Marijuana is certainly pharmacologically active, but that is also true of a large number of compounds that are not medicines, such as dry cleaning fluid. Marijuana may be used to relieve pain and appears to be effective in this role for some people.2 Hence, it is a drug, but then so are many other plants that are not used as prescription medicines such as St John’s wort or belladonna. What characterizes a prescription medicine is that it has an identifiable compound or active ingredient that has a known potency in its pure form; its pharmacokinetics and route of delivery are understood; it is delivered safely; it is manufactured with a consistent formulation; and it has undergone regulatory studies and been approved as having a favourable balance of benefits and harms. Several prescription medicines have already been developed from cannabis,1 but under the proposed new regulations, marijuana itself has none of the above characteristics. Doctors are being asked to prescribe a dried leaf containing several compounds of unspecified potency, some of them active and none of them pure; smoking is an unreliable way to deliver a consistent dose, is probably harmful and no other medicine is administered this way; there is no evidence that those offering to supply marijuana understand how to deliver a consistent drug dose in a smoked product; and, most important, marijuana has not undergone regulatory testing and approval as a medicine.

Marijuana is a drug that is at a similar stage of development to poppy and foxglove in the 19th century. Although doctors may have prescribed those drugs then, in the 21st century we prescribe morphine and digoxin. If the government is serious about asking doctors to prescribe marijuana, it should remove the barriers to developing marijuana as a pharmaceutical product. Then doctors would have a medicine they could prescribe with some knowledge as to its effectiveness and side-effect profile, safe in the knowledge that they are not alone in the firing line should something go wrong. But there is no suggestion in the recent announcement that this is the government’s intention.

The real impetus for change is probably to control the use of this illegal substance and to reduce the risk of fire from home growing operations. In her announcement of the proposed new regulations, Minister of Health Leona Aglukkaq said “Current medical marihuana regulations have left the system open to abuse. We have heard real concerns from law enforcement, fire officials and municipalities about how people are hiding behind these rules to conduct illegal activity and putting health and safety of Canadians at risk.”1 These are real concerns. The number of people authorized to use marijuana has grown faster than was expected from 500 in 2002 to 26 000 today,1 and it is clearly hazardous to grow a regular supply of this flammable resinous plant at home in a basement. But it is muddled thinking to suggest that the solution is for doctors to prescribe it.

It does make sense for doctors to be involved, though. We are at an awkward stage in marijuana’s development because it is a potentially useful, but illegal, herbal product that the government is prepared to tolerate in certain circumstances. It would be much better for the government to specify criteria that must be met for an individual to be permitted to use marijuana. The doctor’s role would then be to certify that a patient met these criteria. This is not the same as a doctor making a diagnosis and deciding to prescribe a drug for a defined indication. This is more akin to certifying that a patient meets the government’s criteria for a disabled parking permit. The doctor does not suggest the patient should drive or that a disabled parking place would be good for them, just that they do fall into the category of person that the government says may have one.

It is time the government made up its mind. Does it want marijuana to become a medicine? If it does, it should work with the pharmaceutical companies to ensure that this is a properly researched and developed drug. At the moment, marijuana is a herbal product and not a medicine. Doctors should not allow themselves to be lulled into prescribing it.

Footnotes

  • Competing interests: See www.cmaj.ca/site/misc/cmaj_staff.xhtml

References

  1. ↵
    Harper government announces proposed new marihuana for medical purposes regulations — changes improve public safety, maintain patient access. Ottawa (ON): Health Canada; 2012. Available: www.hc-sc.gc.ca/ahc-asc/media/nr-cp/_2012/2012-193bkc-eng.php (accessed 2013 Feb. 14).
  2. ↵
    1. Ware MA,
    2. Wang T,
    3. Shapiro S,
    4. et al
    . Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010;182:E694–701.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 185 (5)
CMAJ
Vol. 185, Issue 5
19 Mar 2013
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Marijuana is not a prescription medicine
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Marijuana is not a prescription medicine
John Fletcher
CMAJ Mar 2013, 185 (5) 369; DOI: 10.1503/cmaj.130267

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Marijuana is not a prescription medicine
John Fletcher
CMAJ Mar 2013, 185 (5) 369; DOI: 10.1503/cmaj.130267
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Expanding Medical Marijuana Access in Canada: Considerations for the Rheumatologist
  • Medical marijuana revisited
  • Google Scholar

More in this TOC Section

  • Le sujet de l’heure : l’accès aux soins de santé au Canada
  • Integration of midwifery care in Canada
  • CMAJ’s new guidance on the reporting of race and ethnicity in research articles
Show more Éditorial

Similar Articles

Collections

  • Topics
    • Cannabis

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire